1887

Journal of General Virology header logo

Volume 89, Issue 5

Antibodies against Epstein–Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology Free

Abstract

Immunoglobulin (Ig) A and/or IgG reactivities to several Epstein–Barr virus (EBV) antigens have been used to facilitate diagnosis of nasopharyngeal carcinoma (NPC). However, antibodies against gp78, an EBV membrane glycoprotein, have not been examined to this day. In this study, we utilized Luminex multi-analyte profiling (xMAP) technology to analyse antibody responses to a synthetic peptide of gp78 in sera samples from 95 NPC patients and 91 healthy controls. Our results showed the sensitivity and specificity of IgA-gp78 for NPC diagnosis were 79 and 71 %, respectively, while those of IgG-gp78 were 74 and 73 %, respectively. The IgA and IgG responses to different EBV antigens were not identical within an individual and IgA-gp78 and IgG-gp78 could be complementary to antibodies against viral capsid antigen (VCA), the diffused early antigen (EA-D) and the nuclear antigen EBNA1 for NPC diagnosis. When the six EBV parameters for NPC prediction, i.e. IgA-gp78, IgG-gp78, IgA-VCA, IgA-EBNA1, IgA-EA-D and IgG-EA-D, are combined, the combined predictors were able to reach overall sensitivity and specificity of 91 and 95 %, respectively. Thus, simultaneous detection of these EBV serological markers could improve the predictive values of NPC using xMAP technology.

  • Received:
  • Accepted:
  • Published Online:
SGM
Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83686-0
2008-05-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/5/1152.html?itemId=/content/journal/jgv/10.1099/vir.0.83686-0&mimeType=html&fmt=ahah

References

  1. Amon W., Farrell P. J. 2005; Reactivation of Epstein-Barr virus from latency. Rev Med Virol 15:149–156 [CrossRef]
     [Google Scholar]
  2. Biagini R. E., Sammons D. L., Smith J. P., MacKenzie B. A., Striley C. A., Robertson S. A., Snawder J. E., Quinn C. P. 2005; Simultaneous measurement of specific serum IgG responses to five select agents. Anal Bioanal Chem 382:1027–1034 [CrossRef]
     [Google Scholar]
  3. Busson P., Keryer C., Ooka T., Corbex M. 2004; EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 12:356–360 [CrossRef]
     [Google Scholar]
  4. Chen R., Lowe L., Wilson J. D., Crowther E., Tzeggai K., Bishop J. E., Varro R. 1999; Simultaneous quantification of six human cytokines in a single sample using microparticle-based flow cytometric technology. Clin Chem 45:1693–1694
     [Google Scholar]
  5. Cohen J. I. 2000; Epstein-Barr virus infection. N Engl J Med 343:481–492 [CrossRef]
     [Google Scholar]
  6. Dardari R., Hinderer W., Lang D., Benider A., El Gueddari B., Joab I., Benslimane A., Khyatti M. 2001; Antibody responses to recombinant Epstein-Barr virus antigens in nasopharyngeal carcinoma patients: complementary test of ZEBRA protein and early antigens p54 and p138. J Clin Microbiol 39:3164–3170 [CrossRef]
     [Google Scholar]
  7. Deng H., Zeng Y., Lei Y., Zhao Z., Wang P., Li B., Pi Z., Tan B., Zheng Y. other authors 1995; Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J (Engl) 108:300–303
     [Google Scholar]
  8. Dolyniuk M., Wolff E., Kieff E. 1976; Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus. J Virol 18:289–297
     [Google Scholar]
  9. Dunbar S. A., Vander Zee C. A., Oliver K. G., Karem K. L., Jacobson J. W. 2003; Quantitative, multiplexed detection of bacterial pathogens: DNA and protein applications of the Luminex LabMAP system. J Microbiol Methods 53:245–252 [CrossRef]
     [Google Scholar]
  10. Earley M. C., Vogt R. F. Jr, Shapiro H. M., Mandy F. F., Kellar K. L., Bellisario R., Pass K. A., Marti G. E., Stewart C. C., Hannon W. H. 2002; Report from a workshop on multianalyte microsphere assays. Cytometry 50:239–242 [CrossRef]
     [Google Scholar]
  11. Elshal M. F., McCoy J. P. 2006; Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38:317–323 [CrossRef]
     [Google Scholar]
  12. Epstein M. A., Henle G., Achong B. G., Barr Y. M. 1965; Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma. J Exp Med 121:761–770 [CrossRef]
     [Google Scholar]
  13. Fachiroh J., Schouten T., Hariwiyanto B., Paramita D. K., Harijadi A., Haryana S. M., Ng M. H., Middeldorp J. M. 2004; Molecular diversity of Epstein-Barr virus IgG and IgA antibody responses in nasopharyngeal carcinoma: a comparison of Indonesian, Chinese, and European subjects. J Infect Dis 190:53–62 [CrossRef]
     [Google Scholar]
  14. Fachiroh J., Paramita D. K., Hariwiyanto B., Harijadi A., Dahlia H. L., Indrasari S. R., Kusumo H., Zeng Y. S., Schouten T. other authors 2006; Single-assay combination of Epstein-Barr virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 44:1459–1467 [CrossRef]
     [Google Scholar]
  15. Farrel P. J. 2005; Epstein-Barr virus genome. In Epstein-Barr virus . pp 263–287Edited by Robertson. Norwich, UK: Caister Academic Press;
  16. Feng P., Chan S. H., Soo M. Y., Liu D., Guan M., Ren E. C., Hu H. 2001; Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis. Cancer 92:1872–1880 [CrossRef]
     [Google Scholar]
  17. Fones-Tan A., Chan S. H., Tsao S. Y., Gan L. H., Tan W. H., Li B., Khong P. W., Gan Y. Y. 1994; Enzyme-linked immunosorbent assay (ELISA) for IgA and IgG antibodies to Epstein-Barr-virus ribonucleotide reductase in patients with nasopharyngeal carcinoma. Int J Cancer 59:739–742 [CrossRef]
     [Google Scholar]
  18. Foong Y. T., Cheng H. M., Sam C. K., Dillner J., Hinderer W., Prasad U. 1990; Serum and salivary IgA antibodies against a defined epitope of the Epstein-Barr virus nuclear antigen (EBNA) are elevated in nasopharyngeal carcinoma. Int J Cancer 45:1061–1064 [CrossRef]
     [Google Scholar]
  19. Fulton R. J., McDade R. L., Smith P. L., Kienker L. J., Kettman J. R. Jr 1997; Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 43:1749–1756
     [Google Scholar]
  20. Gastpar H., Wilmes E., Wolf H. 1981; Epidemiologic, etiologic and immunologic aspects of nasopharyngeal carcinoma (NPC). J Med 12:257–284
     [Google Scholar]
  21. Gong M., Ooka T., Matsuo T., Kieff E. 1987; Epstein-Barr virus glycoprotein homologous to herpes simplex virus gB. J Virol 61:499–508
     [Google Scholar]
  22. Gulley M. L. 2001; Molecular diagnosis of Epstein-Barr virus-related diseases. J Mol Diagn 3:1–10 [CrossRef]
     [Google Scholar]
  23. Hadar T., Rahima M., Kahan E., Sidi J., Rakowsky E., Sarov B., Sarov I. 1986; Significance of specific Epstein-Barr virus IgA and elevated IgG antibodies to viral capsid antigens in nasopharyngeal carcinoma patients. J Med Virol 20:329–339 [CrossRef]
     [Google Scholar]
  24. Heineman T., Gong M., Sample J., Kieff E. 1988; Identification of the Epstein-Barr virus gp85 gene. J Virol 62:1101–1107
     [Google Scholar]
  25. Henle G., Henle W. 1976; Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17:1–7 [CrossRef]
     [Google Scholar]
  26. Ho S., Teo P., Kwan W. H., Choi P., Tjong J., Johnson P. J. 1998; Staging and IgA VCA titre in patients with nasopharyngeal carcinoma: changes over a 12-year period. Oral Oncol 34:491–495 [CrossRef]
     [Google Scholar]
  27. Johannsen E., Luftig M., Chase M. R., Weicksel S., Cahir-McFarland E., Illanes D., Sarracino D., Kieff E. 2004; Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci U S A 101:16286–16291 [CrossRef]
     [Google Scholar]
  28. Kettman J. R., Davies T., Chandler D., Oliver K. G., Fulton R. J. 1998; Classification and properties of 64 multiplexed microsphere sets. Cytometry 33:234–243 [CrossRef]
     [Google Scholar]
  29. Khanna R., Burrows S. R., Moss D. J. 1995; Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 59:387–405
     [Google Scholar]
  30. Khanna R., Moss D. J., Burrows S. R. 1999; Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 170:49–64 [CrossRef]
     [Google Scholar]
  31. Klutts J. S., Liao R. S., Dunne W. M. Jr, Gronowski A. M. 2004; Evaluation of a multiplexed bead assay for assessment of Epstein-Barr virus immunologic status. J Clin Microbiol 42:4996–5000 [CrossRef]
     [Google Scholar]
  32. Leung S. F., Tam J. S., Chan A. T., Zee B., Chan L. Y., Huang D. P., Van Hasselt A., Johnson P. J., Lo Y. M. 2004; Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem 50:339–345 [CrossRef]
     [Google Scholar]
  33. Littler E., Baylis S. A., Zeng Y., Conway M. J., Mackett M., Arrand J. R. 1991; Diagnosis of nasopharyngeal carcinoma by means of recombinant Epstein-Barr virus proteins. Lancet 337:685–689 [CrossRef]
     [Google Scholar]
  34. Lukacs Z., Dietrich A., Ganschow R., Kohlschutter A., Kruithof R. 2005; Simultaneous determination of HIV antibodies, hepatitis C antibodies, and hepatitis B antigens in dried blood spots – a feasibility study using a multi-analyte immunoassay. Clin Chem Lab Med 43:141–145
     [Google Scholar]
  35. Mackett M., Conway M. J., Arrand J. R., Haddad R. S., Hutt-Fletcher L. M. 1990; Characterization and expression of a glycoprotein encoded by the Epstein-Barr virus Bam HI I fragment. J Virol 64:2545–2552
     [Google Scholar]
  36. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982; Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes. Proc Natl Acad Sci U S A 79:7504–7508 [CrossRef]
     [Google Scholar]
  37. Old L. J., Boyse E. A., Oettgen H. F., Harven E. D., Geering G., Williamson B., Clifford P. 1966; Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci U S A 56:1699–1704 [CrossRef]
     [Google Scholar]
  38. Pattle S. B., Farrell P. J. 2006; The role of Epstein-Barr virus in cancer. Expert Opin Biol Ther 6:1193–1205 [CrossRef]
     [Google Scholar]
  39. Pickard A., Chen C. J., Diehl S. R., Liu M. Y., Cheng Y. J., Hsu W. L., Sun B., Hsu M. M., Chen I. H. other authors 2004; Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 111:117–123 [CrossRef]
     [Google Scholar]
  40. Raab-Traub N. 2002; Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12:431–441 [CrossRef]
     [Google Scholar]
  41. Raab-Traub N., Flynn K., Klein C., Pizza G., De Vinci C., Occhiuzzi L., Farneti G., Caliceti U., Pirodda E. 1987; EBV associated malignancies. J Exp Pathol 3:449–456
     [Google Scholar]
  42. Skogstrand K., Thorsen P., Norgaard-Pedersen B., Schendel D. E., Sorensen L. C., Hougaard D. M. 2005; Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin Chem 51:1854–1866 [CrossRef]
     [Google Scholar]
  43. Szakonyi G., Klein M. G., Hannan J. P., Young K. A., Ma R. Z., Asokan R., Holers V. M., Chen X. S. 2006; Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol 13:996–1001 [CrossRef]
     [Google Scholar]
  44. Tao Q., Young L. S., Woodman C. B., Murray P. G. 2006; Epstein-Barr virus (EBV) and its associated human cancers -- genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 11:2672–2713 [CrossRef]
     [Google Scholar]
  45. Tarbouriech N., Buisson M., Geoui T., Daenke S., Cusack S., Burmeister W. P. 2006; Structural genomics of the Epstein-Barr virus. Acta Crystallogr D Biol Crystallogr 62:1276–1285 [CrossRef]
     [Google Scholar]
  46. Urquiza M., Lopez R., Patino H., Rosas J. E., Patarroyo M. E. 2005; Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells. J Biol Chem 280:35598–35605 [CrossRef]
     [Google Scholar]
  47. Xu J., Ahmad A., Blagdon M., D'Addario M., Jones J. F., Dolcetti R., Vaccher E., Prasad U., Menezes J. 1998; The Epstein-Barr virus (EBV) major envelope glycoprotein gp350/220-specific antibody reactivities in the sera of patients with different EBV-associated diseases. Int J Cancer 79:481–486 [CrossRef]
     [Google Scholar]
  48. Yip T. T., Ngan R. K., Lau W. H., Poon Y. F., Joab I., Cochet C., Cheng A. K. 1994; A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma. Cancer 74:2414–2424 [CrossRef]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83686-0
Loading
Antibodies against Epstein–Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology
J. Gen. Virol. 89, 1152 (2008); https://doi.org/10.1099/vir.0.83686-0
/content/journal/jgv/10.1099/vir.0.83686-0
/content/journal/jgv/10.1099/vir.0.83686-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error